$0.2372
-0.00170-0.71%
At close: -
$0.2380
0.000800.34%
After Hours: Apr 25, 7:38 PM EDT
Comments
Loading...
Processa Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:PCSA | Benzinga
Processa Pharmaceuticals Inc has a consensus price target of $4.25 based on the ratings of 5 analysts. The high is $6 issued by HC Wainwright & Co. on December 5, 2024. The low is $3 issued by Oppenheimer on April 3, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on December 5, 2024, October 3, 2024, and August 20, 2024, respectively. With an average price target of $6 between HC Wainwright & Co., there's an implied 2421.01% upside for Processa Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Benchmark
Benchmark
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Processa Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/05/2024 | Buy Now | 2421.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2024 | Buy Now | 2421.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/20/2024 | Buy Now | 2421.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/19/2024 | Buy Now | 2421.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | $8 → $6 | Maintains | Buy | Get Alert |
| 08/01/2024 | Buy Now | 3261.34% | HC Wainwright & Co. | Raghuram Selvaraju42% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2024 | Buy Now | 3261.34% | HC Wainwright & Co. | Raghuram Selvaraju42% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 3261.34% | HC Wainwright & Co. | Raghuram Selvaraju42% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 3261.34% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $8 | Initiates | → Buy | Get Alert |
| 03/06/2024 | Buy Now | 1580.67% | Benchmark | Robert Wasserman48% | → $4 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 11/17/2023 | Buy Now | — | Maxim Group | Naz Rahman27% | — | Downgrade | Buy → Hold | Get Alert |
| 04/04/2023 | Buy Now | 1580.67% | Benchmark | Aydin Huseynov34% | $180 → $80 | Maintains | Speculative Buy | Get Alert |
| 04/03/2023 | Buy Now | 1160.5% | Oppenheimer | Francois Brisebois41% | $100 → $60 | Maintains | Outperform | Get Alert |
| 01/12/2023 | Buy Now | 2000.84% | Maxim Group | Naz Rahman27% | $180 → $100 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Processa Pharmaceuticals (PCSA) stock?
The latest price target for Processa Pharmaceuticals (NASDAQ:PCSA) was reported by HC Wainwright & Co. on December 5, 2024. The analyst firm set a price target for $6.00 expecting PCSA to rise to within 12 months (a possible 2421.01% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Processa Pharmaceuticals (PCSA)?
The latest analyst rating for Processa Pharmaceuticals (NASDAQ:PCSA) was provided by HC Wainwright & Co., and Processa Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Processa Pharmaceuticals (PCSA)?
There is no last upgrade for Processa Pharmaceuticals
When was the last downgrade for Processa Pharmaceuticals (PCSA)?
The last downgrade for Processa Pharmaceuticals Inc happened on November 17, 2023 when Maxim Group changed their price target from N/A to N/A for Processa Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Processa Pharmaceuticals (PCSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharmaceuticals was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.
Is the Analyst Rating Processa Pharmaceuticals (PCSA) correct?
While ratings are subjective and will change, the latest Processa Pharmaceuticals (PCSA) rating was a reiterated with a price target of $6.00 to $6.00. The current price Processa Pharmaceuticals (PCSA) is trading at is $0.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
